Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio
- PMID: 19506359
- DOI: 10.1159/000214853
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio
Abstract
Autosomal dominant von Willebrand disease (VWD) type 1/2E is a quantitative/qualitative defect in the von Willebrand factor (VWF) caused by heterozygous cysteine and non-cysteine mutations in the D3 domain of the VWF gene and results in a secretion-multimerization-clearance defect in mutant VWF with the loss of large VWF multimers not due to proteolysis. The multimers of patients with dominant VWD type 1/2E due to mutations in the D3 domain show an aberrant triplet structure with lack of outer bands but with pronounced inner bands of the triplet structure combined with a relative decrease in large multimers reflecting heterozygosity for multimerization defects. There is a good response to desmopressin (DDAVP) followed by rapid clearance of VWF:antigen (Ag), factor VIII coagulant activity (FVIII:C) and VWF:ristocetin cofactor activity (RCo) as the main cause of VWD type 1 or 2 with typical 2E multimeric pattern (VWD type 1/2E). Cysteine mutations in the D3 domains (C1130, C1149 and C1190) show pronounced features of VWD 1/2E with the relative loss of large and relative increase in small VWF multimers with abnormal triplet structure in heterozygotes. Such abnormalities are less pronounced in patients with a milder form of VWD type 1 due to non-cysteine mutations W1144G, T1156M and W1120S in the D3 domain. VWD type 1 Vicenza is caused by the R1205H mutation in the D3 domain and characterized by equally low levels of FVIII:C, VWF:Ag and VWF:RCo. The response to DDAVP in VWD Vicenza is good for FVIII:C, VWF:Ag and VWF:RCo, which is followed by a rapid clearance in less than a few hours of FVIII:C and VWF parameters. The ratios for FVIII:C/VWF:Ag, VWF:RCo/Ag and VWF:CB/Ag remain normal before and after DDAVP indicating that VWD Vicenza clearly differs from VWD type 1, 1/2E and 2M. A new set of missense mutations in D4, B1-B3 and C1-C2 domains has been discovered as the cause of a mild VWD type 1 secretion defect with normal VWF multimers or smeary VWF multimeric pattern. Cysteine mutations in exons 38, 40, 42 and 43 (D4, B1-B3 and C1 domain), show smeary patterns (either smf or sm), with the presence of large VWF multimers and a laboratory phenotype of mild VWD type 1 with variable penetrance of bleeding manifestations. Recent studies showed that the ratio of VWF propeptide (pp) to VWF:Ag can be used to predict a shorter than normal half-life for VWF:Ag. There is a strong inverse correlation between rapid clearance of VWF:Ag after DDAVP and increased VWFpp/Ag ratios >10 in VWD type 1 Vicenza, and >2 in VWD type 1/2E but normal or slightly increased (1-<2) VWFpp/Ag ratios in mild-type VWD due to nonsense or missense mutations in the D1, D2, D4, B and C domains.
Copyright (c) 2009 S. Karger AG, Basel.
Similar articles
-
Laboratory diagnosis and molecular classification of von Willebrand disease.Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506352 Review.
-
Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.Acta Haematol. 2009;121(2-3):85-97. doi: 10.1159/000214847. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506353 Review.
-
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506358 Review.
-
Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.Semin Thromb Hemost. 2005 Nov;31(5):577-601. doi: 10.1055/s-2005-922230. Semin Thromb Hemost. 2005. PMID: 16276467 Review.
-
Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.Acta Haematol. 2009;121(2-3):145-53. doi: 10.1159/000214855. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506361 Review.
Cited by
-
One Health: Animal Models of Heritable Human Bleeding Diseases.Animals (Basel). 2022 Dec 26;13(1):87. doi: 10.3390/ani13010087. Animals (Basel). 2022. PMID: 36611696 Free PMC article. Review.
-
SCO-spondin, a giant matricellular protein that regulates cerebrospinal fluid activity.Fluids Barriers CNS. 2021 Oct 2;18(1):45. doi: 10.1186/s12987-021-00277-w. Fluids Barriers CNS. 2021. PMID: 34600566 Free PMC article. Review.
-
Novel cysteine substitution p.(Cys1084Tyr) causes variable expressivity of qualitative and quantitative VWF defects.Blood Adv. 2022 May 10;6(9):2908-2919. doi: 10.1182/bloodadvances.2021005928. Blood Adv. 2022. PMID: 35020809 Free PMC article.
-
Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.Blood Adv. 2022 Jul 12;6(13):4031-4040. doi: 10.1182/bloodadvances.2022007216. Blood Adv. 2022. PMID: 35452508 Free PMC article.
-
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.Life (Basel). 2021 Mar 5;11(3):202. doi: 10.3390/life11030202. Life (Basel). 2021. PMID: 33807613 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous